Cardiology Section, Durham VA Medical Center, Durham, NC; Division of Cardiology, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Durham, NC.
TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Am Heart J. 2022 Mar;245:29-40. doi: 10.1016/j.ahj.2021.11.008. Epub 2021 Nov 19.
The benefit of an electronic support system for the prescription and adherence to oral anticoagulation therapy among patients with atrial fibrillation (AF) and atrial flutter at heightened risk for of stroke and systemic thromboembolism is unclear.
To evaluate the effect of a combined alert intervention and shared decision-making tool to improve prescription rates of oral anticoagulation therapy and adherence.
DESIGN, SETTING, AND PARTICIPANTS: A prospective single arm study of 939 consecutive patients treated at a large tertiary healthcare system.
An electronic support system comprising 1) an electronic alert to identify patients with AF or atrial flutter, a CHADS-VASc score ≥ 2, and not on oral anticoagulation and 2) electronic shared decision-making tool to promote discussions between providers and patients regarding therapy.
The primary endpoint was prescription rate of anticoagulation therapy. The secondary endpoint was adherence to anticoagulation therapy defined as medication possession ratio ≥ 80% during the 12 months of follow-up.
Between June 13, 2018 and August 31, 2018, the automated intervention identified and triggered a unique alert for 939 consecutive patients with AF or atrial flutter, a CHADS-VASc score ≥2 who were not on oral anticoagulation. The median CHADS-VASc score among all patients identified by the alert was 2 and the median untreated duration prior to the alert was 495 days (interquartile range 123 - 1,831 days). Of the patients identified by the alert, 345 (36.7%) initiated anticoagulation therapy and 594 (63.3%) did not: 68.7% were treated with a non-Vitamin K antagonist oral anticoagulant (NOAC), 22.0% with warfarin, and 9.3 % combination of NOAC and warfarin. Compared with historical anticoagulation rates, the electronic alert was associated with a 23.6% increase in anticoagulation prescriptions. The overall 1-year rate of adherence to anticoagulant therapy was 75.4% (260/345).
An electronic automated alert can successfully identify patients with AF and atrial flutter at high risk for stroke, increase oral anticoagulation prescription, and support high rates of adherence.
在卒中及全身性血栓栓塞风险较高的房颤(AF)和房扑患者中,电子支持系统对处方及口服抗凝治疗的依从性的益处尚不清楚。
评估联合警示干预和共享决策工具在提高口服抗凝治疗处方率和依从性方面的效果。
设计、地点和参与者:一项在大型三级医疗保健系统中连续治疗的 939 例患者的前瞻性单臂研究。
电子支持系统包括 1)电子警示以识别 AF 或房扑、CHADS-VASc 评分≥2 且未接受口服抗凝治疗的患者,以及 2)电子共享决策工具以促进提供者和患者之间关于治疗的讨论。
主要终点为抗凝治疗处方率。次要终点为抗凝治疗依从性,定义为在 12 个月随访期间药物使用率≥80%。
2018 年 6 月 13 日至 2018 年 8 月 31 日,自动化干预措施识别并触发了 939 例连续 AF 或房扑、CHADS-VASc 评分≥2 且未接受口服抗凝治疗的患者的独特警示。所有被警示识别出的患者的中位 CHADS-VASc 评分为 2 分,在警示前未接受治疗的中位时间为 495 天(四分位距 123-1831 天)。在被警示识别出的患者中,345 例(36.7%)开始抗凝治疗,594 例(63.3%)未接受抗凝治疗:68.7%接受非维生素 K 拮抗剂口服抗凝剂(NOAC)治疗,22.0%接受华法林治疗,9.3%接受 NOAC 和华法林联合治疗。与历史抗凝率相比,电子警示与抗凝治疗处方增加了 23.6%相关。总的 1 年抗凝治疗依从率为 75.4%(260/345)。
电子自动化警示可以成功识别卒中风险较高的 AF 和房扑患者,增加口服抗凝治疗处方,并支持高依从率。